<DOC>
	<DOCNO>NCT00987727</DOCNO>
	<brief_summary>This study evaluate safety efficacy OPTIVEÂ® MD ocular surface integrity symptomatic dry eye condition absence obvious eye-lid inflammation .</brief_summary>
	<brief_title>Safety Efficacy Carboxymethylcellulose Ocular Surface Integrity Symptomatic Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>Have use artificial tear least 3 month prior study inclusion Have use preservative free artificial tear least three time daily ( TIB ) least 2 week immediately prior study inclusion Having moderate severe symptom suggestive dry eye Current enrollment investigational drug device study participation study within 3 month prior entry study Moderate severe blepharitis History active sign ocular trauma , ocular infection , ocular inflammation within last 3 month History active sign ocular allergic disease ocular herpes within last year History active sign severe serious ocular condition inflammatory corneal ulcer , recurrent erosion , uveitis time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>